Stuttgart
24.10.25 | 07:38
16,420 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | XVIVO Perfusion AB: Interim Report January-September 2025 | 135 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 23, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2025 (Jul-Sep)Net sales amounted to SEK 189.1 million (198.5), corresponding to growth... ► Artikel lesen | |
| 13.10. | XVIVO Perfusion AB: Conference Call on Interim Report July-September 2025 | 259 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / October 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report July-September... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 05.09. | Nomination Committee of XVIVO Perfusion AB | 224 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / September 5, 2025 / The following members have been appointed to XVIVO Perfusion's (STO:XVIVO)(LSE:0RKL)(FRA:3XV) nomination committee for the 2026 annual general... ► Artikel lesen | |
| 28.07. | XVIVO Perfusion AB: Delay in CE Approval for XVIVO's Perfusion Solution for Heart Preservation | 480 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / July 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV). The XVIVO Heart Assist Transport and the XVIVO Heart Assist Transport Perfusion Set have received... ► Artikel lesen | |
| 22.07. | Xvivo enrolls first patient in Heart Assist Transport device study | 2 | MassDevice | ||
| 21.07. | XVIVO Perfusion AB: First Patient Enrolled in US PRESERVE CAP Study for XVIVO Heart Assist Transport Device | 287 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 21, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announces that the first patient has been enrolled as part of the Continued Access... ► Artikel lesen | |
| 11.07. | XVivo Q2 2025: Umsatzrückgang lässt Aktie einbrechen | 21 | Investing.com Deutsch | ||
| 11.07. | XVIVO Perfusion AB: Interim Report January-June 2025 | 327 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 11, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)A quarter showing a mixed pictureSecond quarter 2025 (Apr-Jun)• Net sales amounted to SEK 178.3 million... ► Artikel lesen | |
| 11.07. | Marktgegenwind bremst XVIVO: Organisches Wachstum im zweiten Quartal um 11 % rückläufig | 4 | Investing.com Deutsch | ||
| 11.07. | XVIVO Q2 2025 slides reveal -11% organic growth amid market headwinds | 2 | Investing.com | ||
| 10.07. | XVIVO Perfusion AB: Conference Call on Interim Report April-June 2025 | 352 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 10, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2025. The... ► Artikel lesen | |
| 13.06. | XVIVO Perfusion AB: XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market | 305 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA)... ► Artikel lesen | |
| 29.04. | XVIVO Perfusion AB: XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston | 328 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented... ► Artikel lesen | |
| 25.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 401 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | XVIVO Perfusion AB: Interim Report January-March 2025 | 293 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to growth... ► Artikel lesen | |
| 15.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 | 400 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.... ► Artikel lesen | |
| 02.04. | XVIVO Perfusion AB: Annual Report 2024 | 381 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
| 20.03. | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 359 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen | |
| 28.01. | XVIVO Perfusion AB: Year-End Report 2024 | 347 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2024 (October 1 - December 31)• Net sales amounted to SEK 227.6 million (155.7), corresponding... ► Artikel lesen | |
| 13.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2024 | 433 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 17,550 | -0,62 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| UNITEDHEALTH | 312,00 | +0,10 % | Nächstes Beben: Molina Healthcare crasht - UnitedHealth schwach | Die US-Krankenversicherer kommen nicht zur Ruhe. Am Mittwochabend hat der Gesundheitsdienstleister Molina Healthcare die Anleger mit enttäuschenden Zahlen erneut verunsichert. Die Aktie brach daraufhin... ► Artikel lesen | |
| INTUITIVE SURGICAL | 470,85 | +0,19 % | Vor den Zahlen: Intuitive Surgical: Jetzt Rebound-Chance vor den Earnings? | © Foto: Christian Charisius/dpaIntuitive Surgical ist ein innovatives US-Unternehmen und arbeitet im Bereich robotergestützter Chirurgie erfolgreich. Doch die Aktie ließ zuletzt Federn. Am Dientag sind... ► Artikel lesen | |
| RHOEN-KLINIKUM | 11,700 | 0,00 % | RHÖN-KLINIKUM Campus Bad Neustadt erneut als Schwerpunktzentrum Hypertonie zertifiziert | Bad Neustadt a.d. Saale (ots) - Die Klinik für kardiologische Rehabilitation am RHÖN-KLINIKUM Campus Bad Neustadt wurde erneut von der Deutschen Hochdruckliga e. V. (DHL®) als "Schwerpunktzentrum Hypertonie"... ► Artikel lesen | |
| HIMS & HERS HEALTH | 42,000 | +0,17 % | GRAIL-Aktie dreht schon wieder auf: Krebserkennungstest verblüfft - Hims & Hers investiert | Der positive Newsflow beim US-amerikanischen Krebsdiagnostik-Spezialisten GRAIL reißt nicht ab. Weitere Daten zum Bluttest zur Früherkennung mehrerer Krebsarten (Name: Galleri) unterstreichen den positiven... ► Artikel lesen | |
| BICO GROUP | 2,034 | -0,49 % | BICO Group AB: Maria Rankka appointed Board Chair of BICO Group AB | The Board of Directors has with immediate effect among its members elected Maria Rankka to serve as Board Chair of BICO Group AB, until a new chair has been elected by the shareholders' meeting. Maria... ► Artikel lesen | |
| M1 KLINIKEN | 14,100 | -1,81 % | M1 Kliniken-Tochter Hameato verkauft Pharmasparte an Phoenix | Die M1 Kliniken AG hat mitgeteilt, dass ihre 85-Prozent-Beteiligung Hameato AG die 100-Prozent-Tochtergesellschaft Hameato Pharm GmbH an die Phoenix group verkauft hat. Zu den finanziellen Details machten... ► Artikel lesen | |
| BAXTER | 19,866 | +0,39 % | Solventum hires Baxter EVP and COO Heather Knight for new C-suite role | ||
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| JD HEALTH INTERNATIONAL | 6,950 | 0,00 % | JD HEALTH Forms In Vitro Diagnostics Alliance with Multiple IVD Brands | ||
| LIFEWARD | 0,648 | -0,31 % | Lifeward Ltd.: Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| COOPER COMPANIES | 63,50 | 0,00 % | Price Over Earnings Overview: Cooper Companies | ||
| SURGICAL SCIENCE SWEDEN | 8,180 | 0,00 % | Surgical Science Sweden AB: Sales in the second quarter were weak, which together with large currency effects weighed on the result | According to the preliminary reporting, Surgical Science's sales for the second quarter amounted to approximately SEK 209 million, a decrease of 2% compared to the second quarter of 2024. For the various... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,540 | -0,78 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results | ||
| SOLENO THERAPEUTICS | 55,15 | -0,09 % | Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET |
XVIVO PERFUSION AB gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 16,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.